Compare GSK plc (GSK) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lithium Americas Corp — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while Lithium Americas Corp trades at $3.33 (market cap $1.18B). The key difference: GSK plc is far larger — about 86.9× Lithium Americas Corp's market cap, and GSK plc pays a 3.57% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| GSK | LAC | |
|---|---|---|
Market Cap | $102.60B | $1.18B |
Sector | Health | Basic Materials |
52-Week High | $61.18 | $10.05 |
52-Week Low | $38.22 | $2.71 |
Enterprise Value | $123.04B | $1.29B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Lithium Americas (LAC) trades at $3.26, showing modest daily gains of 0.31%. The stock exhibits a bullish technical signal with mixed quarterly earnings performance, beating estimates twice but missing significantly in Q4 2025. Recent $175 million financing strengthens the balance sheet as Thacker Pass approaches peak construction. The company maintains negative profitability metrics with ROE at -11.35% but trades below book value at P/B of 0.88.
Investment outlook remains speculative with significant execution risk at Thacker Pass requiring substantial capital expenditures. Analyst consensus leans cautious with 47% buy ratings versus 53% holds. Positive catalysts include lithium demand growth and government support, but cash burn and dilution risks persist for equity holders amid ongoing development phase.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
